mGlu3 PAM for neurodegenerative disorders

mGlu3 PAM for the treatment of neurodegenerative disorders.

We are developing mGlu3 PAM as a novel orally available treatment for neurodegenerative disorders.  

Scientific evidence suggests astroglial mGlu3 receptor activation leads to neuroprotection, through modulation of glutamate excitotoxicity and glutamate transport, neurotrophin production and reduction of oxidative damage, pointing to the potential utility of mGlu3 PAMs for neurodegenerative disorders such as Alzheimer’s or Parkinson’s diseases.  

We are currently optimizing multiple chemical series of highly selective mGlu3 PAMs.